BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36265908)

  • 1. Predicting Outcomes of Indeterminate Bone Lesions on
    Phelps TE; Harmon SA; Mena E; Lindenberg L; Shih JH; Citrin DE; Pinto PA; Wood BJ; Dahut WL; Gulley JL; Madan RA; Choyke PL; Turkbey B
    J Nucl Med; 2023 Mar; 64(3):395-401. PubMed ID: 36265908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: clinical and PET/CT features to predict outcomes and prognosis.
    Luo L; Wang Z; Wang X; Gao J; Zheng A; Duan X
    Clin Radiol; 2024 May; 79(5):346-353. PubMed ID: 38216370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
    Chen MY; Franklin A; Yaxley J; Gianduzzo T; McBean R; Wong D; Tatkovic A; McEwan L; Walters J; Kua B
    BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Comparison of PET Imaging with PSMA-Targeted
    Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Predicting Metastatic Disease in
    Chiu LW; Lawhn-Heath C; Behr SC; Juarez R; Perez PM; Lobach I; Bucknor MD; Hope TA; Flavell RR
    J Nucl Med; 2020 Dec; 61(12):1779-1785. PubMed ID: 32303599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of [
    Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched-Pair Comparison of
    Rauscher I; Krönke M; König M; Gafita A; Maurer T; Horn T; Schiller K; Weber W; Eiber M
    J Nucl Med; 2020 Jan; 61(1):51-57. PubMed ID: 31253741
    [No Abstract]   [Full Text] [Related]  

  • 9. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
    Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical insignificance of [
    Arnfield EG; Thomas PA; Roberts MJ; Pelecanos AM; Ramsay SC; Lin CY; Latter MJ; Garcia PL; Pattison DA
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4495-4507. PubMed ID: 34136957
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
    Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68 Ga-PSMA-11 PET Features to Predict Metastasis After Biochemical Recurrence.
    Letang A; Crombé A; Rousseau C; Sargos P; Merlin C; Cantarel C; Cazeau AL
    Clin Nucl Med; 2022 Aug; 47(8):e529-e539. PubMed ID: 35543633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of
    Zacho HD; Nielsen JB; Afshar-Oromieh A; Haberkorn U; deSouza N; De Paepe K; Dettmann K; Langkilde NC; Haarmark C; Fisker RV; Arp DT; Carl J; Jensen JB; Petersen LJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unspecific
    Seifert R; Telli T; Opitz M; Barbato F; Berliner C; Nader M; Umutlu L; Stuschke M; Hadaschik B; Herrmann K; Fendler WP
    J Nucl Med; 2023 May; 64(5):738-743. PubMed ID: 36460340
    [No Abstract]   [Full Text] [Related]  

  • 15. Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study.
    Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; van Leeuwen PJ; van der Poel HG
    J Nucl Med; 2022 Oct; 63(10):1531-1536. PubMed ID: 36008118
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
    J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
    Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
    J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    Shanmugasundaram R; Saad J; Heyworth A; Wong V; Pelecanos A; Arianayagam M; Canagasingham B; Ferguson R; Goolam AS; Khadra M; Kam J; Ko R; McCombie S; Varol C; Winter M; Mansberg R; Nguyen D; Bui C; Loh H; Le K; Roberts MJ
    BJU Int; 2024 Feb; 133 Suppl 3():25-32. PubMed ID: 37943964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.